GoAI
Get started
HCW Biologics Inc. logo

HCW Biologics Inc.

HCWB

NASDAQHealthcareBiotechnology

Open in GoAI

Latest quote

$2.31

+$0.13 · +5.96%

Aug 24, 4:00 PM ET

HCWB company overview

Regular session · ET · Market data may be delayed.

GoAI snapshot

AI-powered factor overview

Jul 10, 2026

GoAI score

Sell

Trim exposure — unfavorable risk-reward

Valuation

46

Fair Value

Momentum

17

Strong Down

Sentiment

61

Bullish

Risk resilience

20

High Risk

Full GoAI research

Thesis, catalysts, evidence, and risk analysis.

View full GoAI research

AI-generated, informational only, and not investment advice.

Company profile

Company website

HCW Biologics Inc. operates as a preclinical-stage biopharmaceutical firm, primarily engaged in the discovery and advancement of novel immunotherapies. Its research and development efforts are focused on addressing chronic, low-grade inflammation and a spectrum of age-related diseases. The company's leading therapeutic candidates include HCW9218, an injectable immunotherapeutic designed for patients with a variety of cancers, such as pancreatic, ovarian, breast, prostate, and colorectal, as well as for pulmonary fibrosis. Another key product, HCW9302, targets autoimmune conditions like alopecia areata and various metabolic disorders. Beyond these, HCW Biologics is also developing HCW9201, a cell-based therapy currently in Phase II clinical trials for the treatment of relapsed/refractory acute myeloid leukemia. Additionally, HCW9206 is under development specifically for acute myeloid leukemia. Incorporated in 2018, the company's corporate headquarters are situated in Miramar, Florida.

Industry
Biotechnology
Sector
Healthcare
Headquarters
US
CEO
Hing C. Wong
Listed since
Jul 20, 2021
Employees
35

Market position

Day range

Current $2.31

52-week range

Current $2.31

Open
$2.32
Previous close
$2.18
Volume
0
0× average
Average volume
2.05M
Average daily volume
Market cap
803.05K USD
Beta
2.36
Market reference 1
50-day average
$4.255
-45.71% below average
200-day average
$6.4996
-64.46% below average

Financials

Financial statements

Margin trends

Profitability as a percentage of reported revenue.

Gross marginOperating marginNet margin
Gross, operating, and net margin trends2118%-6200%-14519%-22837%Gross margin, FY2022: 38.48%Gross margin, FY2023: 19.72%Gross margin, FY2024: 37.38%Gross margin, FY2025: 20.00%Operating margin, FY2022: -224.32%Operating margin, FY2023: -904.96%Operating margin, FY2024: -1148.50%Operating margin, FY2025: -20757.65%Net margin, FY2022: -221.67%Net margin, FY2023: -879.52%Net margin, FY2024: -1169.70%Net margin, FY2025: -14677.14%FY2021FY2022FY2023FY2024FY2025
Gross margin FY2022 38.48%. Gross margin FY2023 19.72%. Gross margin FY2024 37.38%. Gross margin FY2025 20.00%. Operating margin FY2022 -224.32%. Operating margin FY2023 -904.96%. Operating margin FY2024 -1148.50%. Operating margin FY2025 -20757.65%. Net margin FY2022 -221.67%. Net margin FY2023 -879.52%. Net margin FY2024 -1169.70%. Net margin FY2025 -14677.14%.

Income trends

Revenue

54.23K USD-97.89%

Operating income

−11.26M USD+61.81%

Net income

−7.96M USD+73.49%
Income trends across reported periods10.4M USD−4.3M USD−19M USD−33.7M USDRevenue, FY2022: 6.72M USDRevenue, FY2023: 2.84M USDRevenue, FY2024: 2.57M USDRevenue, FY2025: 54.23K USDOperating income, FY2021: −13.37M USDOperating income, FY2022: −15.08M USDOperating income, FY2023: −25.72M USDOperating income, FY2024: −29.48M USDOperating income, FY2025: −11.26M USDNet income, FY2021: −12.86M USDNet income, FY2022: −14.9M USDNet income, FY2023: −24.99M USDNet income, FY2024: −30.02M USDNet income, FY2025: −7.96M USDFY2021FY2022FY2023FY2024FY2025
Revenue FY2022 6.72M USD. Revenue FY2023 2.84M USD. Revenue FY2024 2.57M USD. Revenue FY2025 54.23K USD. Operating income FY2021 −13.37M USD. Operating income FY2022 −15.08M USD. Operating income FY2023 −25.72M USD. Operating income FY2024 −29.48M USD. Operating income FY2025 −11.26M USD. Net income FY2021 −12.86M USD. Net income FY2022 −14.9M USD. Net income FY2023 −24.99M USD. Net income FY2024 −30.02M USD. Net income FY2025 −7.96M USD.
Metric (USD)FY2025FY2024FY2023FY2022FY2021
Revenue54.23K USD2.57M USD2.84M USD6.72M USD—
Cost of goods sold43.39K USD1.61M USD2.28M USD4.14M USD—
Gross profit10.85K USD959.4K USD560.36K USD2.59M USD—
Research and development5.44M USD6.39M USD7.68M USD9.34M USD8.17M USD
Selling, general, and administrative7.7M USD21.95M USD13.08M USD7.99M USD5.3M USD
Operating expenses11.27M USD30.44M USD26.28M USD17.67M USD13.37M USD
Interest income————505.37K USD
Interest expense1.25M USD1.16M USD283.04K USD126.66K USD—
Depreciation and amortization1.04M USD1.18M USD1.14M USD717.85K USD543.6K USD
Operating income−11.26M USD−29.48M USD−25.72M USD−15.08M USD−13.37M USD
Net income−7.96M USD−30.02M USD−24.99M USD−14.9M USD−12.86M USD

Company facts updated Aug 24, 2026.

HCWB peers

Amgen Inc. logo

AMGN

Amgen Inc.

$443.84

+1.03%

Gilead Sciences, Inc. logo

GILD

Gilead Sciences, Inc.

$146.74

+0.42%

Vertex Pharmaceuticals Incorporated logo

VRTX

Vertex Pharmaceuticals Incorporated

$547.59

-0.08%

Intuitive Surgical, Inc. logo

ISRG

Intuitive Surgical, Inc.

$373.57

-1.38%

Sanofi logo

SNY

Sanofi

$45.69

-0.35%

Regeneron Pharmaceuticals, Inc. logo

REGN

Regeneron Pharmaceuticals, Inc.

$828.5

-0.66%

ETFs holding HCWB

Funds reporting this stock among their holdings, ordered by reported position size.

Vanguard Extended Market ETF logoVanguard Extended Market ETFVXF
Market value
6.42K
Weight
0.00%
AUM
93.7B USD
Expense ratio
0.05%
Price / 1D
$243.4-0.87%

Continue in GoAI

Research HCWB

research.disclaimer